Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Nearly everyone ... serious diseases. Yet few people realize that a rich source of these cells is ... adults, and teeth that need to be pulled to make room for braces. ...
(Date:7/28/2015)... ... 2015 , ... The new Xsample 530 sample changer for vials can be used ... viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external air) – ... catches the eye about Xsample 530 is its removable magazine, which is easily lifted off ...
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2New Moves in Automatic Sample Handling: Introducing Xsample 530 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... , , ... AB (publ),and BioChromix AB announced today the formation of BioChromix Pharma ... its unique,knowledge of molecular chemistry. Karolinska Development will initially take,28 percent ... are very excited about BioChromix Pharma as they have a novel,approach ...
... , ... supports Higher Education and Local Youth by establishing Five College Scholarships. The first ... pursue Bio-Technology studies at NoVA. The company will also sponsor four scholarships for ... ...
... Jan. 13 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... the introduction of new products during a presentation today at the ... the brief presentation, limited by conference organizers to 10 minutes per ... in its cosmetics line during 2010. They include an eye cream ...
Cached Biology Technology:Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3RiVIdium Inc. Creates Five Local Scholarships 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 3
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... on the Cohen Y chromosome indicates the Jewish priesthood, the ... a single male lineage dating to ancient Hebrew times. ... Jewish priesthood that traced its patrilineal dynasty and seemed to ... (and brother of Moses), was one of a number of ...
... A scientist at the La Jolla Institute for Allergy & ... (NIH),s top awards -- the 2009 NIH Director,s Pioneer Award. ... costs of up to $4.7 million over five years, and ... whose novel proposals offer the potential to make extraordinary contributions ...
... RICHLAND, Wash. -- An analytical chemist at the Department ... with a National Institutes of Health Director,s New Innovator ... make new research and clinical diagnostic tools that are ... The award, which comes with a $1.5 million, ...
Cached Biology News:New genetic research indicates Jewish priesthood has multiple lineages 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 3Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 4PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
... (Ser385) Immunogen: ... acid region encompassing the human, ... Accession Number: ... Quality Assurance: Routinely evaluated ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
TNR-R2...
Biology Products: